Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal ...
People also ask
Is AKBA stock a good buy?
What is the price target for Akebia Therapeutics?
Who owns AKBA?
Will Vadadustat get FDA approval?
For the latest news from Akebia, visit our Investors page. VIEW ALL NEWS. BC-0014 (v6.0) 03/24. Akebia Therapeutics, Inc. 245 First Street, Suite 1400
Find annual and quearterly earnings data for Akebia Therapeutics, Inc. Common Stock (AKBA) including earnings per share, earnings forecasts at Nasdaq.com.
Mar 14, 2024 · (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial ...
Akebia Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View AKBA financial statements in full.
Rating
(2,975)
Akebia Therapeutics (AKBA) will release its next earnings report on May 5, 2024. In the last quarter Akebia Therapeutics reported -$0.038 EPS in relation to ...
Get the latest insights on Akebia Therapeutics, Inc. Common Stock (AKBA) with press releases and corporate news to help you in your trading and investing ...